The pharmaceutical landscape is evolving rapidly, with advanced drug discovery and biotherapeutics paving the way for next-generation treatments. Yet, the R&D process remains hindered by the sheer complexity and volume of biomedical data. From multi-omics profiling and target identification to preclinical development, valuable data is often trapped in fragmented spreadsheets, siloed legacy systems, or unconnected lab databases.

At Elucidata, we help global biopharma companies break free from these data bottlenecks. Our platform, Polly, and our specialized Research Informatics solutions provide a unified foundation for your entire R&D lifecycle. We automate the ingestion, curation, and harmonization of complex multi-modal data bytransforming unstructured biomedical data into high-quality, ML-ready assets.

Whether you are optimizing early-stage target discovery, building custom bioinformatics pipelines, or preparing data for predictive AI and foundation models, we turn your "messy" biological data into an asset that accelerates candidate selection and drastically reduces manual effort.

Meet our team at CPHI Japan 2026 to learn how we are helping top biopharmaceutical companies scale their data infrastructure, slash research costs by up to 70%, and bring innovative therapies to market faster.